Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
BioSpace recently spoke with Mir Imran, CEO and Chief Innovator at Rani Therapeutics, a company developing and testing a “robotic” pill that delivers biologics orally.
BioSpace caught up with Charles Fuchs, M.D., SVP, Global Head of Oncology & Hematology Product Development, Genentech during the ASCO meeting on personalized cancer care.
Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.
The $7 billion transaction by Datavant with Ciox Health will be the nation’s largest “neutral and secure health data ecosystem.”
Despite controversy over the drug’s effectiveness, it appears to have spiked interest in investing in Alzheimer’s drug companies, something that had been on the decline for several years.
Unicorn Hunters is a new Internet reality show where startup companies can pitch a group of well-known panelists dubbed the “Circle of Money” which allows for a kind of crowdsourced funding appeal.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 8, 2021.
As a result of the termination, argenx will regain worldwide rights to cusatuzumab, its anti-CD70 antibody, from Cilag FmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
In the field of drug discovery, one must always begin with the target, right? Not if you ask Cellarity, a quickly emerging biotech company revolutionizing the drug development space.
The three companies will aim to develop their different programs such as Stablix TPS platform, Stellanova’s focused on targeting pro-tumorigenic effects, and Amyl’s development of preclinical therapeutic candidates.